Overview

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The current gold standard for treatment of chronic hepatitis C (CHC) patients is with pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegPen. The goal of this study is to determine the satisfaction grade with this novel device.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Interferon-alpha
Peginterferon alfa-2b
Ribavirin